BioSpace News Archive

Survey reveals many U.S. adults are more aware of less common and less deadly conditions than they are of sepsis, which takes a life every two minutes.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC.

Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, today announced the appointment of Shakti Narayan, J.D., Ph.D., as its Chief Executive Officer and a member of the Board of Directors.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) today announced it will reduce debt by approximately $200 million through the prepayment of senior secured term loans and the redemption of outstanding senior notes, using cash flow from operations.

Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference to be held September 9-11, 2019, in New York, NY.

IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery, announced today an exclusive distribution agreement with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY: OTC US)

Developments in the Frontiers of Diagnosis and Treatment for Bipolar Disorder and Schizophrenia Receive Extensive Attention

Polpharma Biologics S.A. announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar.

Calliditas Therapeutics AB announced that it has obtained written feedback from the US Food and Drug Administration that will have a significant impact on the ongoing pivotal Phase 3 study, NefIgArd, with Calliditas’ leading drug candidate Nefecon for the chronic autoimmune kidney disease IgA Nephropathy.

Inotrem S.A. announced that the U.S. Food and Drug Administration has granted Fast Track designation to nangibotide development program for the treatment of septic shock.